Novartis Expert Denies Zometa Caused Bone Death In NJ Trial

Law360, New York (May 9, 2013, 9:04 PM EDT) -- Novartis Pharmaceuticals Corp. couldn't win a midtrial judgment Thursday in a New Jersey lawsuit in multicounty litigation over its bone drug Zometa, but did begin calling witnesses to combat claims that it failed to adequately disclose risks of jaw bone death and that the drug was responsible for the plaintiff's jaw problems.

Shortly after Middlesex County Superior Court Judge Jessica Mayer denied its motion for a directed verdict, Novartis called its first witness in the case, University of Oxford Professor Dr. Graham Russell. With Russell's testimony,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.